Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $35.35 USD
Change Today +1.01 / 2.94%
Volume 36.7M
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
London
Sao Paulo
Bogota
As of 8:04 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Key Developments

Pfizer Inc. Announces Consolidated Financial Results for the Second Quarter and Six Months of 2015; Provides Earnings Guidance for the Full Year 2015

Pfizer Inc. announced consolidated financial results for the second quarter and six months of 2015. For the quarter, the company reported revenue of $11.853 million against $12.773 million a year ago. Adjusted income was $3.525 million against $3.769 million a year ago. Adjusted diluted EPS was $0.56 against $0.58 a year ago. Reported net income was $2.626 million or $0.42 per diluted share against $2.912 million or $0.45 per diluted share a year ago. Reported revenues decreased $920 million, or 7%, which reflects operational growth of $125 million, or 1%, more than offset by the unfavorable impact of foreign exchange of $1.0 billion, or 8%. Excluding the impact of foreign exchange, adjusted diluted EPS increased by approximately 6%. For the six months, the company reported revenue of $22.717 million against $24.126 million a year ago. Adjusted income was $6.721 million against $7.434 million a year ago. Adjusted diluted EPS was $1.07 against $1.15 a year ago. Reported net income was $5.002 million or $0.80 per diluted share against $5.241 million or $0.81 per diluted share a year ago. For the year of 2015, the company now expects adjusted revenues in a range of $45 to $46 billion as compared to $44 to $46 billion expected earlier; effective tax rate is expected to be approximately 25.0%; Diluted EPS is expected to be in a range of $1.38 to $1.47 as compared to $1.32 to $1.47 expected earlier; and adjusted diluted EPS is expected to be in a range of $2.01 to $2.07 as compared to $1.95 to $2.05 expected earlier.

Pfizer Announces Expansion of Lease Agreement with Massachusetts Institute of Technology

Pfizer announced the expansion of its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus in Kendall Square (KSQ). With this expansion, Pfizer has leased the full 500,000 square feet at 610 Main Street in Kendall Square. This space will continue to house the R&D activities that relocated to 610 Main Street in 2014, and will enable the consolidation of Pfizer's three other leased spaces in Cambridge into the one campus. This most recent lease addition secures an added 130,000 square feet of space for potential expansion in the future and will be available for sub-tenancy in 2017. Once the three remote sites are consolidated, 610 Main Street will house approximately 1,000 Pfizer employees. Pfizer's R&D efforts in Cambridge will continue to focus on rare diseases, cardiovascular and metabolic disease, inflammation and immunology, neuroscience, and advanced bio-therapeutic technologies. The expanded 370,000-plus square foot KSQ research center will help foster a strong laboratory culture, with experimentation and collaboration in the heart of Cambridge's Kendall Square innovation hub, featuring labs and an open design to help foster breakthrough productivity and innovation that will potentially advance Pfizer's pipeline.

Pfizer to Close its Navi Mumbai Plant

Pfizer has decided to close its plant situated at Thane Belapur Road, K.U. Bazar P.O., Navi Mumbai - 400705 with effect from September 16, 2015. The decision to close the Plant is based on an assessment of its long term viability and its ability to achieve the needed production. There has practically been no production activity at this plant since 2013, and the closure will not impact the supply of any of Company medicines to patients. The decision to close the plant is based on an assessment of its long term viability and its ability to achieve the needed production.

Pfizer Launches Center of Excellence Precision Medicine in Santiago, Chile

Pfizer has launched the Center of Excellence Precision Medicine (CEMP) in Santiago, Chile. The CEMP will be focus on developing new technologies for the molecular diagnosis of cancer. The centre is the result of a joint effort between the Chilean Center of Excellence incentive programme of the Production Development Corporation (Corfo), which provided USD 7 million in funds, and Pfizer, which invested USD 14 million.

Pfizer Inc. Announces the Enrollment of the First Patient in Phase 2b Clinical Trial of its Investigational Staphylococcus Aureus

Pfizer Inc. announced the enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery. The purpose of the study, named STRIVE (STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy), is to evaluate the safety and efficacy of the vaccine to determine if it prevents postoperative invasive S. aureus infections in patients undergoing elective spinal surgery. Surgical Site Infections (SSIs) are a significant and growing concern. SSIs caused by S. aureus account for approximately 20% of all SSIs in the U.S., and are associated with an estimated annual treatment cost of $12.3 billion in the U.S.2,3 Patients who suffer such infections due to antibiotic resistant (MRSA) or antibiotic sensitive (MSSA) S.aureus have worse clinical outcomes, including increased mortality in comparison with non-infected patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:US $35.35 USD +1.01

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $339.50 USD +12.52
Gilead Sciences Inc $113.07 USD +2.53
Johnson & Johnson $99.02 USD +0.74
Nestle SA SFr.72.55 CHF +0.65
Procter & Gamble Co/The $80.23 USD +0.26
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 23.8x
Price/Sales 4.3x
Price/Book 3.1x
Price/Cash Flow 16.2x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.